
Brain Cancer Diagnostics Market by Test Type (Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan), Brain Cancer Type (Acoustic Neuroma, Astrocytomas, Chordomas), End-User - Global Forecast 2024-2030
Description
Brain Cancer Diagnostics Market by Test Type (Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan), Brain Cancer Type (Acoustic Neuroma, Astrocytomas, Chordomas), End-User - Global Forecast 2024-2030
The Brain Cancer Diagnostics Market size was estimated at USD 4.02 billion in 2023 and expected to reach USD 4.52 billion in 2024, at a CAGR 12.44% to reach USD 9.14 billion by 2030.
Global Brain Cancer Diagnostics Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Brain Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Brain Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Brain Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Associated Regional and University Pathologists, Inc., Becton, Dickinson and Company, Bristol Myers Squibb Co., F. Hoffmann-La Roche AG by Roche Holding AG, Fujifilm Holdings Corporation, GE Healthcare, Grail, LLC, Henry Ford Health, Hitachi, Ltd., Hologic, Inc., Illumina, Inc., Invitae Corporation, Koninklijke Philips N.V., Laboratory Corporation of America Holdings, NantOmics, NeoGenomics Laboratories, Inc., Novocure GmbH, Oncologica Limited, Quibim, S.L., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..
Market Segmentation & Coverage
This research report categorizes the Brain Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Test Type
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
PET Scan
Spinal Tap
Brain Cancer Type
Acoustic Neuroma
Astrocytomas
Chordomas
Ependymomas
End-User
Diagnostic Centers
Hospitals & Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Brain Cancer Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Brain Cancer Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Brain Cancer Diagnostics Market?
4. What is the market share of the leading vendors in the Brain Cancer Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Brain Cancer Diagnostics Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Brain Cancer Diagnostics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing incidence of brain cancer
- 5.1.1.2. Growth in the number of private diagnostic centers and rising public-private partnerships
- 5.1.2. Restraints
- 5.1.2.1. Heavy costs associated with diagnosis and low awareness about the diagnosis
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancement in diagnostics devices
- 5.1.3.2. Development of diagnostic approaches for various cancer mutations
- 5.1.4. Challenges
- 5.1.4.1. Rising risk of high radiation exposure and stringent regulatory guidelines
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Brain Cancer Diagnostics Market, by Test Type
- 6.1. Introduction
- 6.2. Magnetic Resonance Imaging
- 6.3. Magnetic Resonance Spectroscopy
- 6.4. PET Scan
- 6.5. Spinal Tap
- 7. Brain Cancer Diagnostics Market, by Brain Cancer Type
- 7.1. Introduction
- 7.2. Acoustic Neuroma
- 7.3. Astrocytomas
- 7.4. Chordomas
- 7.5. Ependymomas
- 8. Brain Cancer Diagnostics Market, by End-User
- 8.1. Introduction
- 8.2. Diagnostic Centers
- 8.3. Hospitals & Clinics
- 9. Americas Brain Cancer Diagnostics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Brain Cancer Diagnostics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Brain Cancer Diagnostics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Associated Regional and University Pathologists, Inc.
- 13.1.3. Becton, Dickinson and Company
- 13.1.4. Bristol Myers Squibb Co.
- 13.1.5. F. Hoffmann-La Roche AG by Roche Holding AG
- 13.1.6. Fujifilm Holdings Corporation
- 13.1.7. GE Healthcare
- 13.1.8. Grail, LLC
- 13.1.9. Henry Ford Health
- 13.1.10. Hitachi, Ltd.
- 13.1.11. Hologic, Inc.
- 13.1.12. Illumina, Inc.
- 13.1.13. Invitae Corporation
- 13.1.14. Koninklijke Philips N.V.
- 13.1.15. Laboratory Corporation of America Holdings
- 13.1.16. NantOmics
- 13.1.17. NeoGenomics Laboratories, Inc.
- 13.1.18. Novocure GmbH
- 13.1.19. Oncologica Limited
- 13.1.20. Quibim, S.L.
- 13.1.21. Siemens Healthineers AG
- 13.1.22. Thermo Fisher Scientific, Inc.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. BRAIN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
- FIGURE 2. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. BRAIN CANCER DIAGNOSTICS MARKET DYNAMICS
- FIGURE 7. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
- FIGURE 8. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2023 VS 2030 (%)
- FIGURE 10. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 12. BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.